The Latest Analyst Ratings for Corvus Pharma
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Corvus Pharma (NASDAQ:CRVS) stock, with an average 12-month price target of $5.25, up 75% from the previous average of $3.00. The ratings include 1 bullish, 1 somewhat bullish, and 2 indifferent.
June 16, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corvus Pharma (NASDAQ:CRVS) has an average 12-month price target of $5.25, up 75% from the previous average, with 1 bullish, 1 somewhat bullish, and 2 indifferent analyst ratings.
The average 12-month price target for Corvus Pharma has increased by 75% over the past 3 months, indicating a positive outlook from analysts. With 1 bullish and 1 somewhat bullish rating, the stock is likely to experience an upward trend in the short term. The 2 indifferent ratings may not have a significant impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100